SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat
Panayotis K Vlachakis, Panagiotis Theofilis, Dimitris Tousoulis · 2024
Read SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat by Panayotis K Vlachakis, Panagiotis Theofilis, Dimitris Tousoulis (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11586729.txt.
Description
Heart failure (HF) is a major global health challenge, particularly among individuals with type 2 diabetes mellitus (T2DM), who are at significantly higher risk of developing HF. Diabetic cardiomyopathy, a unique form of heart disease, often progresses silently until advanced stages.
Catalog record
| CREATOR | Panayotis K Vlachakis, Panagiotis Theofilis, Dimitris Tousoulis |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |